Citadel Advisors LLC
- SEC CIK
- 0001423053
- Latest filing
- Sep 1, 2026
CRVS holding history
Corvus Pharmaceuticals, Inc. in every 13F filed by Citadel Advisors LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
CRVS overviewAll 13F holders of CRVSFull Q2 2026 holdings
- Shares (Q2 2026)
- 397,951
- Value
- $5.95M
- % of portfolio
- <0.1%
- Quarters held
- 15
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 397,951 | $5.95M | <0.1% | −44,571−10.1% | Reduced | Holders |
| Q1 2026 | 442,522 | $6.47M | <0.1% | +234,340+112.6% | Added | Holders |
| Q4 2025 | 208,182 | $1.60M | <0.1% | +165,416+386.8% | Added | Holders |
| Q3 2025 | 42,766 | $315.2K | <0.1% | +42,766 | New | Holders |
| Q2 2025 | 0 | $0 | 0.0% | −61,676−100.0% | Sold out | Holders |
| Q1 2025 | 61,676 | $196.1K | <0.1% | −17,036−21.6% | Reduced | Holders |
| Q4 2024 | 78,712 | $421.1K | <0.1% | −18,361−18.9% | Reduced | Holders |
| Q3 2024 | 97,073 | $512.5K | <0.1% | +44,063+83.1% | Added | Holders |
| Q2 2024 | 53,010 | $96.5K | <0.1% | +53,010 | New | Holders |
| Q1 2024 | 0 | $0 | 0.0% | −7,654−100.0% | Sold out | Holders |
| Q4 2023 | 7,654 | $13.5K | <0.1% | +7,471+4,082.5% | Added | Holders |
| Q3 2023 | 183 | $267 | <0.1% | +183 | New | Holders |
| Q1 2023 | 0 | $0 | 0.0% | −1,015−100.0% | Sold out | Holders |
| Q4 2022 | 1,015 | $863 | <0.1% | +1,015 | New | Holders |
| Q2 2022 | 0 | $0 | 0.0% | −404,545−100.0% | Sold out | Holders |
| Q1 2022 | 404,545 | $663.0K | <0.1% | +336,465+494.2% | Added | Holders |
| Q4 2021 | 68,080 | $165.0K | <0.1% | +68,080 | New | Holders |
| Q3 2021 | 0 | $0 | 0.0% | −29,278−100.0% | Sold out | Holders |
| Q2 2021 | 29,278 | $78.0K | <0.1% | −34,993−54.4% | Reduced | Holders |
| Q1 2021 | 64,271 | $198.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.